Latest news about Oxygenta Pharmaceutical
Oxygenta Pharmaceutical
50.49
+0.43(+0.86%)
Company Performance:
View Company Insights1D+0.86%
1M+4.12%
6M-11.59%
1Y-52.28%
5Y+131.71%
More news about Oxygenta Pharmaceutical
04Feb 26
Oxygenta Pharmaceutical Reports Higher Q3 FY26 Loss Despite Revenue Growth
Oxygenta Pharmaceutical Limited reported a net loss of ₹484.30 lakhs for Q3 FY26 ended December 31, 2025, compared to ₹392.82 lakhs in Q3 FY25, despite revenue growth to ₹3,393.09 lakhs from ₹3,320.61 lakhs. For nine months, the company recorded losses of ₹1,591.42 lakhs on revenue of ₹6,336.79 lakhs. The Board also approved re-constitution of the Internal Complaints Committee under POSH Act.
17Dec 25
Virupaksha Organics Increases Stake in Oxygenta Pharma to 55.90%
Virupaksha Organics Limited has increased its stake in Oxygenta Pharmaceutical Limited by acquiring 1,95,885 equity shares through open market purchases. This acquisition has raised Virupaksha Organics' shareholding from 55.37% to 55.90%, representing a 0.53% increase.
11Dec 25
Oxygenta Pharmaceutical Completes Promoter Reclassification with Regulatory Approval
Oxygenta Pharmaceutical successfully reclassified four promoter group shareholders to public category through postal ballot with overwhelming 99.98% approval. The process involved 9.42 lakh shares representing 2.55% equity capital and received BSE's regulatory clearance, ensuring full compliance with SEBI Regulation 31A requirements.
22Oct 25
Oxygenta Pharmaceutical Faces 7-Day Manufacturing License Suspension for Four Key Drugs
Oxygenta Pharmaceutical Limited, a subsidiary of Virupaksha Organics Limited, received a seven-day suspension order for its manufacturing license from the Drugs Control Administration (DCA), Telangana. The suspension, effective from October 21, 2025, affects the production of four drugs: Etoricoxib, Vildagliptin, Lacosamide, and Telmisartan. The company estimates a potential revenue loss of Rs. 20.00 lakhs during this period. The suspension follows violations of rules under the Drugs and Cosmetics Act, 1940 and Rules 1945. The company's manufacturing license remains valid until April 23, 2028, but permission for the specified products is temporarily suspended.
16Oct 25
Oxygenta Pharmaceutical Receives BSE Approval for Promoter Reclassification
Oxygenta Pharmaceutical Limited has received approval from BSE Limited to reclassify four individuals from 'Promoter/Promoter Group' to 'Public' category. The approval, granted on October 16, 2025, follows the company's application on August 29, 2025. The reclassification involves Sai Sudhakar Vankineni, Snigdha Vankineni, Sumanth Simha Vankineni, and Jhansi Rani Vankineni. Oxygenta must now seek shareholder approval, comply with SEBI regulations, and make necessary disclosures regarding this change in shareholding structure.
25Aug 25
Oxygenta Pharmaceutical Undergoes Major Leadership Shake-up and Promoter Reclassification
Oxygenta Pharmaceutical reported significant changes including the resignation of Managing Director and CFO Mr. Vankineni Sai Sudhakar and Independent Director Mr. Sanagari Kondal Reddy. The board approved reclassification of four promoter group shareholders to public shareholders. Board committees were restructured with new appointments. The company's Annual General Meeting for FY 2024-25 is scheduled for September 19, 2025, via video conferencing.
19Aug 25
Oxygenta Pharmaceutical: Four Promoters Seek Reclassification Amid Management Changes
Oxygenta Pharmaceutical Limited is undergoing significant changes in its ownership and management structure. Four promoters, holding a combined 2.55% equity, have requested reclassification from 'Promoter' to 'Public' category. Simultaneously, the company announced the resignations of Managing Director and CFO Vankineni Sai Sudhakar and Independent Director Sanagari Kondal Reddy, effective August 18, 2025. The company will comply with SEBI regulations for the reclassification process, with the promoters confirming their adherence to regulatory requirements.
18Aug 25
Oxygenta Pharmaceutical Announces Key Leadership Resignations Amid Ownership Change
Oxygenta Pharmaceutical Limited, a subsidiary of Virupaksha Organics Limited, announced significant leadership changes. Managing Director and CFO Vankineni Sai Sudhakar and Independent Director Sanagari Kondal Reddy have resigned, effective August 18, 2025. Both cited the change in ownership and management as the reason for their departures. The company, known for its ISO certifications, made the disclosure in compliance with SEBI regulations. Executive Director Balasubba Reddy Mamilla signed the regulatory filing.
Industry Peers
Sun Pharmaceutical
Divis Laboratories
Torrent Pharmaceuticals
Cipla
Zydus Life Science
Lupin
Mankind Pharma
Dr Reddys Laboratories
Laurus Labs
Aurobindo Pharma
1,963.50
(-1.36%)
8,585.00
(+6.57%)
5,050.00
(-1.42%)
1,474.40
(+0.08%)
1,121.00
(-0.51%)
2,393.00
(-0.91%)
2,483.00
(+0.54%)
1,180.00
(+2.78%)
1,811.40
(-0.26%)
1,554.70
(-1.61%)
we are part of Raise Financial Services
built with love
for indians who love to invest & trade
Market Community
Follow us on
